Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476485 | 1.00 | MIF (0.65) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL2488965 | 0.82 | MIF (0.74) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL2488962 | 0.82 | MIF (0.74) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL6444640 | 0.79 | MIF (1.00) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL6444643 | 0.79 | MIF (1.00) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL13401232 | 0.79 | MIF (0.78) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL5373502 | 0.78 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL17290220 | 0.78 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL13903557 | 0.78 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL5373505 | 0.78 | MIF (0.76) | MIFRAB9ASMN1; SMN2NPC1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227977-A1 | Substituted 1,2,5,10-tetrahydropyridazino [4,5-b]quinoline-1,10-dione compounds and methods for the treatment of pain | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | US | disclosed |
| EP-1244663-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| US-20030176435-A1 | Compounds and methods for the treatment of pain | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176435-A1 | Compounds and methods for the treatment of pain | OPRK1, OPRM1, OPRD1 | MIF 4583/4885RAB9A 2281/4885SMN1; SMN2 133/4885 |
| US-20050227977-A1 | Substituted 1,2,5,10-tetrahydropyridazino [4,5-b]quinoline-1,10-dione compounds and methods for the treatment of pain | QDPR, OPRK1, OPRM1 | MIF 4854/4885RAB9A 1809/4885SMN1; SMN2 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.